Literature DB >> 10360631

Inhibitory effect of a new anti-rheumatic drug T-614 on costimulatory molecule expression, cytokine production, and antigen presentation by synovial cells.

A Kawakami1, M Tsuboi, S Urayama, N Matsuoka, S Yamasaki, A Hida, T Aoyagi, I Furuichi, T Nakashima, K Migita, Y Kawabe, M Nakashima, T Origuchi, K Eguchi.   

Abstract

The present study was undertaken to investigate the immunoregulatory effects of T-614 (3-formylamino-7-methylsulfonylamino-6-phenoxy-4H-1-benzopyran-4-o ne) on synovial cells in vitro. Synovial cells were cultured with T-614 in the presence or absence of various cytokines. After incubation, the costimulatory molecule expression on synovial cells and cytokine production in culture supernatants were analyzed by an indirect immunofluorescence method and enzyme-linked immunosorbent assay, respectively. We also examined the effect of T-614 on the function of synovial cells as antigen-presenting cells (APCs). The costimulatory molecules including CD54, CD58, and CD106 were constitutionally expressed on the surface of synovial cells. However, neither CD80 nor CD86 nor CD102 was found on the surface, and these costimulatory molecules could not be induced by any cytokines. T-614 itself did not affect the costimulatory molecule expression and cytokine production of unstimulated synovial cells. The stimulation of synovial cells with interferon-gamma (IFN-gamma), interleukin-1beta, or 12-O-tetradecanoyl phorbol 13-acetate enhanced the expression of costimulatory molecules and the proinflammatory cytokine production of these cells. Both the up-regulated expression of these costimulatory molecules and the enhanced production of proinflammatory cytokines were significantly inhibited by T-614. Autologous T cell proliferation in response to purified protein derivative by IFN-gamma-treated synovial cells was significantly suppressed by T-614. T-614 has considerable immunosuppressive effects on synovial cells by inhibiting the costimulatory molecule expression and cytokine production of these cells and the antigen-specific T cell proliferation mediated by the synovial cells. These results suggest that T-614 plays an important immunoregulatory role in rheumatoid synovial tissues.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10360631     DOI: 10.1016/s0022-2143(99)90186-5

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  9 in total

1.  A randomized phase I study to evaluate the safety, tolerability, pharmacokinetics and food-effect of Iguratimod in healthy adult volunteers.

Authors:  Feng Xiao; Feng Zhang; Ling-Ling Zhang; Wei Wei
Journal:  Eur J Clin Pharmacol       Date:  2017-10-19       Impact factor: 2.953

2.  Identification of Iguratimod as an Inhibitor of Macrophage Migration Inhibitory Factor (MIF) with Steroid-sparing Potential.

Authors:  Joshua Bloom; Christine Metz; Saisha Nalawade; Julian Casabar; Kai Fan Cheng; Mingzhu He; Barbara Sherry; Thomas Coleman; Thomas Forsthuber; Yousef Al-Abed
Journal:  J Biol Chem       Date:  2016-10-28       Impact factor: 5.157

3.  Anti-rheumatic drug iguratimod (T-614) alleviates cancer-induced bone destruction via down-regulating interleukin-6 production in a nuclear factor-κB-dependent manner.

Authors:  Yue Sun; Da-Wei Ye; Peng Zhang; Ying-Xing Wu; Bang-Yan Wang; Guang Peng; Shi-Ying Yu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2016-10-18

4.  Efficacy and safety of iguratimod combined with methotrexate vs. methotrexate alone in rheumatoid arthritis : A systematic review and meta-analysis of randomized controlled trials.

Authors:  L-J Chen; Y-J Zhou; Z-H Wen; F Tian; J-Y Li
Journal:  Z Rheumatol       Date:  2020-12-21       Impact factor: 1.372

5.  Regulatory Effect of Iguratimod on the Balance of Th Subsets and Inhibition of Inflammatory Cytokines in Patients with Rheumatoid Arthritis.

Authors:  Yunzhi Xu; Qi Zhu; Jinglve Song; Hongli Liu; Yutong Miao; Fan Yang; Feiyan Wang; Wenjing Cheng; Yebin Xi; Xiaoyin Niu; Dongyi He; Guangjie Chen
Journal:  Mediators Inflamm       Date:  2015-12-02       Impact factor: 4.711

Review 6.  Iguratimod: a valuable remedy from the Asia Pacific region for ameliorating autoimmune diseases and protecting bone physiology.

Authors:  Jie Li; Jun Bao; Jian Zeng; Aizhu Yan; Chunqiu Zhao; Qiang Shu
Journal:  Bone Res       Date:  2019-09-03       Impact factor: 13.567

7.  Iguratimod prevents ovariectomy‑induced bone loss and suppresses osteoclastogenesis via inhibition of peroxisome proliferator‑activated receptor‑γ.

Authors:  Ying-Xing Wu; Yue Sun; Ya-Ping Ye; Peng Zhang; Jia-Chao Guo; Jun-Ming Huang; Xing-Zhi Jing; Wei Xiang; Shi-Ying Yu; Feng-Jing Guo
Journal:  Mol Med Rep       Date:  2017-09-28       Impact factor: 2.952

8.  Novel disease-modifying anti-rheumatic drug iguratimod suppresses chronic experimental autoimmune encephalomyelitis by down-regulating activation of macrophages/microglia through an NF-κB pathway.

Authors:  Guangrui Li; Ryo Yamasaki; Mei Fang; Katsuhisa Masaki; Hirofumi Ochi; Takuya Matsushita; Jun-Ichi Kira
Journal:  Sci Rep       Date:  2018-01-31       Impact factor: 4.379

Review 9.  Iguratimod as a New Drug for Rheumatoid Arthritis: Current Landscape.

Authors:  Sisi Xie; Shu Li; Jing Tian; Fen Li
Journal:  Front Pharmacol       Date:  2020-02-26       Impact factor: 5.810

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.